Denise Pedrosa

Denise Pedrosa

Auto-generated profile, based on publicly available information

Denise Pedrosa

Center for Thrombosis and Hemostasis (K.Z., M.L.B., D.P., K.K., W.R., C.R.), University Medical Center Mainz, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2021 in Science
Verified
Journal Article
Closed access
PDF file
NMNadine Müller-Calleja
Nadine Müller-Calleja
AHAnne Hollerbach
Anne Hollerbach
JRJennifer Royce
Jennifer Royce
SRSvenja Ritter
Svenja Ritter
DPDenise Pedrosa
Denise Pedrosa
WRWolfram Ruf
Wolfram Ruf
A lipid-protein autoimmunity target: Several autoimmune diseases, including systemic lupus erythematosus and primary antiphospholipid syndrome, are characterized by the presence of antiphospholipid antibodies (aPLs). These molecules can activate the complement and coagulation cascades, which contributes to pathologies such as thrombosis, stroke, and pregnancy complications. Müller-Calleja et al. found that endothelial protein C receptor (EPCR) in complex with lysobisphosphatidic acid (LBPA) is the cell-surface target for aPL and mediates its internalization (see the Perspective by Kaplan). aPL binding to EPCR-LBPA resulted in the activation of tissue factor–mediated coagulation and interferon-α production by dendritic cells. Interferon-α, in turn, fueled the expansion of B1a cells, which secrete aPLs. The specific blockade of this target in mice inhibited the development of aPL autoimmunity, offering hope for future therapies for these conditions. Science , this issue p. eaay1833 ; see also p. 1100

21 August 2019 in Blood
Verified
Journal Article
Open access
PDF file
NMNadine Müller-Calleja
Nadine Müller-Calleja
AHAnne Hollerbach
Anne Hollerbach
SRSvenja Ritter
Svenja Ritter
DPDenise G. Pedrosa
Denise G. Pedrosa
DSDennis Strand
Dennis Strand
WRWolfram Ruf
Wolfram Ruf
Antiphospholipid antibody syndrome is caused by antiphospholipid antibodies (aPLs) that cause thrombosis and pregnancy loss. In a Plenary Paper, Müller-Calleja et al dissect the complex and multifaceted mechanism by which aPLs induce thrombosis through priming of monocytes and disruption of the balance of tissue factor activation and inhibition.

10 May 2024 in Circulation Research
Verified
Journal Article
Closed access
PDF file
KZKonstantinos Zifkos
Konstantinos Zifkos
MBMagdalena L. Bochenek
Magdalena L. Bochenek
RGRajinikanth Gogiraju
Rajinikanth Gogiraju
SRStéphane Robert
Stéphane Robert
DPDenise Pedrosa
Denise Pedrosa
KSKatrin Schäfer
Katrin Schäfer
BACKGROUND: Endothelial activation promotes the release of procoagulant extracellular vesicles and inflammatory mediators from specialized storage granules. Endothelial membrane exocytosis is controlled by phosphorylation. We hypothesized that the absence of PTP1B (protein tyrosine phosphatase 1B) in endothelial cells promotes venous thromboinflammation by triggering endothelial membrane fusion and exocytosis. METHODS: Mice with inducible endothelial deletion of PTP1B (End.PTP1B-KO) underwent inferior vena cava ligation to induce stenosis and venous thrombosis. Primary endothelial cells from transgenic mice and human umbilical vein endothelial cells were used for mechanistic studies. RESULTS: Vascular ultrasound and histology showed significantly larger venous thrombi containing higher numbers of Ly6G (lymphocyte antigen 6 family member G)-positive neutrophils in mice with endothelial PTP1B deletion, and intravital microscopy confirmed the more pronounced neutrophil recruitment following inferior vena cava ligation. RT 2 PCR profiler array and immunocytochemistry analysis revealed increased endothelial activation and adhesion molecule expression in primary End.PTP1B-KO endothelial cells, including CD62P (P-selectin) and VWF (von Willebrand factor). Pretreatment with the NF-κB (nuclear factor kappa B) kinase inhibitor BAY11-7082, antibodies neutralizing CD162 (P-selectin glycoprotein ligand-1) or VWF, or arginylglycylaspartic acid integrin-blocking peptides abolished the neutrophil adhesion to End.PTP1B-KO endothelial cells in vitro. Circulating levels of annexin V + procoagulant endothelial CD62E + (E-selectin) and neutrophil (Ly6G + ) extracellular vesicles were also elevated in End.PTP1B-KO mice after inferior vena cava ligation. Higher plasma MPO (myeloperoxidase) and Cit-H3 (citrullinated histone-3) levels and neutrophil elastase activity indicated neutrophil activation and extracellular trap formation. Infusion of End.PTP1B-KO extracellular vesicles into C57BL/6J wild-type mice most prominently enhanced the recruitment of endogenous neutrophils, and this response was blunted in VWF-deficient mice or by VWF-blocking antibodies. Reduced PTP1B binding and tyrosine dephosphorylation of SNAP23 (synaptosome-associated protein 23) resulting in increased VWF exocytosis and neutrophil adhesion were identified as mechanisms, all of which could be restored by NF-κB kinase inhibition using BAY11-7082. CONCLUSIONS: Our findings show that endothelial PTP1B deletion promotes venous thromboinflammation by enhancing SNAP23 phosphorylation, endothelial VWF exocytosis, and neutrophil recruitment.

21 March 2024 in Blood
Verified
Journal Article
Closed access
PDF file
NMNadine Mueller-Calleja
Nadine Mueller-Calleja
KGKristin Grunz
Kristin Grunz
TNThanh Son Nguyen
Thanh Son Nguyen
JPJens Posma
Jens Posma
DPDenise Pedrosa
Denise Pedrosa
WRWolfram Ruf
Wolfram Ruf
Antiphospholipid antibodies (aPL) in primary or secondary antiphospholipid syndrome (APS) are a major cause for acquired thrombophilia, but specific interventions preventing autoimmune aPL development are an unmet clinical need. Although autoimmune aPL cross react with various coagulation regulatory proteins, lipid-reactive aPL, including those derived from patients with COVID-19, recognize the endolysosomal phospholipid lysobisphosphatidic acid presented by the cell surface–expressed endothelial protein C receptor. This specific recognition leads to complement-mediated activation of tissue factor (TF)–dependent proinflammatory signaling and thrombosis. Here, we show that specific inhibition of the TF coagulation initiation complex with nematode anticoagulant protein c2 (NAPc2) prevents the prothrombotic effects of aPL derived from patients with COVID-19 in mice and the aPL–induced proinflammatory and prothrombotic activation of monocytes. The induction of experimental APS is dependent on the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex, and NAPc2 suppresses monocyte endosomal reactive oxygen species production requiring the TF cytoplasmic domain and interferon-α secretion from dendritic cells. Latent infection with murine cytomegalovirus causes TF cytoplasmic domain–dependent development of persistent aPL and circulating phospholipid-reactive B1 cells, which is prevented by short-term intervention with NAPc2 during acute viral infection. In addition, treatment of lupus prone MRL-lpr mice with NAPc2, but not with heparin, suppresses dendritic-cell activation in the spleen, aPL production and circulating phospholipid-reactive B1 cells, and attenuates lupus pathology. These data demonstrate a convergent TF-dependent mechanism of aPL development in latent viral infection and autoimmune disease and provide initial evidence that specific targeting of the TF initiation complex has therapeutic benefits beyond currently used clinical anticoagulant strategies.

1 March 2019 in Thrombosis Research
Verified
Journal Article
Closed access
MTMaiara Terra
Maiara Terra
DPDenise G. Pedrosa
Denise G. Pedrosa
CZClaudio Cesar Zoppi
Claudio Cesar Zoppi
CWClaudio C. Werneck
Claudio C. Werneck
CVCristina Vicente
Cristina Vicente